CMDB7 Reduces Tumor Growth and Angiogenesis in Mice
Author Information
Author(s): Hamma-Kourbali Y, Starzec A, Vassy R, Martin A, Kraemer M, Perret G, Crépin M
Primary Institution: Laboratoire de Ciblage Fonctionnel des Tumeurs Solides, Université Paris 13
Hypothesis
Does carboxymethyl benzylamide dextran (CMDB7) inhibit tumor growth and angiogenesis in VEGF-overexpressing human epidermoid carcinoma?
Conclusion
CMDB7 significantly inhibits tumor growth and reduces endothelial cell density in a mouse model of human epidermoid carcinoma.
Supporting Evidence
- CMDB7 treatment resulted in a 73% reduction in tumor growth after 2 weeks.
- Endothelial cell density in tumors decreased by 66% with CMDB7 treatment.
- CMDB7 inhibited the binding of VEGF165 to A431 cells, reducing their proliferation.
Takeaway
A special substance called CMDB7 helps stop tumors from growing and makes it harder for them to get blood from the body.
Methodology
The study involved in vitro and in vivo experiments using human epidermoid carcinoma A431 cells in nude mice, assessing the effects of CMDB7 on tumor growth and angiogenesis.
Potential Biases
Potential bias in the selection of treatment groups and the assessment of outcomes.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Nude mice (athymic, 4 weeks old) were used for the in vivo experiments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website